XNASEPRX
Market cap108mUSD
Dec 24, Last price
3.06USD
1D
-1.13%
1Q
19.34%
IPO
3.56%
Name
Eupraxia Pharmaceuticals Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
13.42%
Rev. gr., 5y
%
Revenues
0k
Net income
-37m
L+60.76%
CFO
-28m
L+48.68%
Earnings
Jun 06, 2025
Profile
Eupraxia Pharmaceuticals Inc., a clinical stage biotechnology company, engages in the discovery, development, and marketing of technologies in the biotechnology sector. The company's lead product candidate is EP-104IAR, which is in a Phase II clinical trial for the treatment of unmet medical needs and for pain relief for knee osteoarthritis, as well as under development for treating canine and equine osteoarthritis. Its products in development also include EP-201, an antibiotic for post-surgical site infections; and EP-105, an extended-release post-surgical anesthetic for post-surgical pain. In addition, the company develops product candidates for oncology. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012.Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.
IPO date
Mar 09, 2021
Employees
21
Domiciled in
CA
Incorporated in
CA
Valuation
Title CAD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | |
| Income | |||||||
Revenues | |||||||
Cost of revenue | 37,405 | 23,204 | 18,678 | ||||
Unusual Expense (Income) | |||||||
NOPBT | (37,405) | (23,204) | (18,678) | ||||
NOPBT Margin | |||||||
Operating Taxes | (90) | 931 | (1,344) | ||||
Tax Rate | |||||||
NOPAT | (37,316) | (24,134) | (17,334) | ||||
Net income | (37,392) 60.76% | (23,259) 1.17% | (22,990) 475.14% | ||||
Dividends | |||||||
Dividend yield | |||||||
Proceeds from repurchase of equity | 15,887 | 13,298 | 37,833 | ||||
BB yield | |||||||
| Debt | |||||||
Debt current | 13,831 | 176 | 155 | ||||
Long-term debt | 53 | 10,508 | 9,599 | ||||
Deferred revenue | |||||||
Other long-term liabilities | |||||||
Net debt | (5,457) | (14,052) | (20,147) | ||||
| Cash flow | |||||||
Cash from operating activities | (27,916) | (18,776) | (14,642) | ||||
CAPEX | (308) | (432) | |||||
Cash from investing activities | (99) | 8,701 | (14,450) | ||||
Cash from financing activities | 27,843 | 13,523 | 49,915 | ||||
FCF | (37,222) | (24,241) | (26,442) | ||||
| Balance | |||||||
Cash | 19,342 | 24,736 | 29,901 | ||||
Long term investments | |||||||
Excess cash | 19,342 | 24,736 | 29,901 | ||||
Stockholders' equity | (12,588) | (6,601) | 22,253 | ||||
Invested Capital | 27,596 | 28,510 | 6,856 | ||||
ROIC | |||||||
ROCE | |||||||
| EV | |||||||
Common stock shares outstanding | 24,147 | 19,285 | 14,243 | ||||
Price | |||||||
Market cap | |||||||
EV | |||||||
EBITDA | (37,195) | (23,011) | (18,566) | ||||
EV/EBITDA | |||||||
Interest | 1,579 | 1,588 | 1,297 | ||||
Interest/NOPBT | |||||||